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Literature Review
1.1 Crimean-Congo haemorrhagic fever virus
1.1.1 Introduction
Crimean-Congo haemorrhagic fever (CCHF) is a highly infectious, life
threatening disease caused by the Crimean-Congo haemorrhagic fever virus
(CCHFV), a bunyavirus in the genus Nairovirus, family Bunyaviridae. The
virus can be found across Asia, Africa and Europe; endemic regions include the
Balkan Peninsula, Southern Russia, and most of sub-Saharan Africa (Leblebi-
cioglu, 2010). The first reported cases of CCHFV infection occurred in 1944
amongst military workers, on the Crimean Peninsula of the then, Union of
Soviet Socialist Republics (USSR) (Hoogstraal, 1979). It was not until 1967,
when the virus was propagated in suckling white mice, that the morphological,
antigenic and physiological characteristics were determined. This led to the
discovery that Congo Haemorrhagic Fever (CHF) was antigenically identical
to a virus isolated in what was then Zaire, now called the Democratic Re-
public of Congo, in 1956. The virus was then renamed to the now familiar




The Nairovirus genus is named after Nairobi sheep disease virus (Crabtree
et al., 2009). The genus contains 3 notable pathogens, in CCHFV, Dugbe
virus and Nairobi sheep disease virus (Clerx et al., 1981).
CCHFV has a single stranded negative sense RNA genome, consisting of
3 strands: small (S), medium (M) and large (L). The S segment codes for
a nucleocapsid protein (NP) that associates with the viral RNA to form a
ribonucleocapsid. This protein is the most abundant viral protein produced by
CCHFV and has been shown to produce a strong, specific humoral antibody
response (Marriott and Nuttall, 1992). It is for this reason that indirect ELISA
diagnostic tests use the N protein (Samudzi et al., 2012).
Figure 1.1: CCHFV genomic structure. Single stranded, negative sense
RNA genome, consisting of 3 strands: small (S), medium (M) and large (L).
Source:ViralZone:www.expasy.org/viralzone SIB Swiss Institute of Bioinfor-
matics
The M segment encodes two glycoproteins, Gn and Gc, that are transcribed
and translated as a single protein and modified post-translationally into two
separate proteins; these glycoproteins play a role in both cell-type recognition
and viral entry. The M segment also encodes for a small non-structural protein
(Nsm) that is hypothesised to play a role in viral assembly. The L segment
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codes for a RNA-dependent RNA polymerase that is responsible for viral
RNA transcription (Figure 1.1).
All bunyaviruses have spherical virions of approximately 100 µm in diame-
ter. The virion is enveloped, with Gn/Gc glycoprotein heterodimers extruding
from the membrane across the surface of the virion (Figure 1.2).
Figure 1.2: Structure of an enveloped, spherical CCHF virion which is ap-
proximately 100µm in diameter. Source:ViralZone:www.expasy.org/viralzone
SIB Swiss Institute of Bioinformatics
1.1.3 CCHFV vectors and infection.
CCHFV has been isolated from a range of ticks, spanning 31 species and
7 genera. It has been found in both hard-bodied ixodid ticks (29 species) and
soft-bodied argasid ticks (2 species) (Hoogstraal, 1979). The majority of these
ticks, however, are not considered to be vectors for CCHFV and in the case of
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argasid ticks, 4 different species have been independently shown to be repli-
cation incompetent hosts. There is a strong correlation between distribution
of ticks from the Hyalomma genus and the distribution of CCHF infections.
This association has led to the conclusion that ticks belonging to the genus
Hyalomma are the primary infectious vectors for CCHFV (Hoogstraal, 1979).
Ixodid ticks follow a three-stage developmental pathway transforming
from larvae into nymphs and finally maturing into adults. The larvae hatch
from eggs laid by the female, and then attach to a host; this is normally a
small vertebrate, such as a small mammal or bird. Once engorged on blood,
they detach and molt into nymphs. The feeding and molting cycle is repeated
again, after which they finally emerge as mature adults. The female adult
ticks attach to large hosts to feed and lay eggs. The males have been observed
to feed scarcely and their primary reason for attaching to large hosts is for
mating purposes (Allan, 2001).
Transient viraemia has been demonstrated in a large percentage of small
mammals in Africa, Asia and Europe. In some cases, they are able to transmit
the virus to new ticks. The same is true of many large mammals, especially
the preferred hosts of Hyalomma ticks, such as buffalo, zebra, rhinoceros and
giraffe. The virus causes inapparent infection or mild fever and viraemia in
its non-human hosts. Transmission occurs when a tick feeds on a host during
viraemia and then feeds on an uninfected host during its subsequent life cycle
stage. It is believed that the rate of transovarial transmission is too low to
allow for the perpetuation of the virus. It is thus hypothesised that small
mammals serve as a reservoir for the virus, infecting ticks during the nymph
phase and allowing transmission to larger vertebrates (Hoogstraal, 1979).
Birds in general have been shown only to develop low levels of viraemia
and it is believed that infection of ticks from birds does not occur (Shepherd
et al., 1987). There is however, evidence of a phenomenon called nonviraemic
transmission, where ticks carrying the virus pass it on to non-infected ticks
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on the same host. Birds also play host to the nymph life stage of the ticks
and thus could play a role in the dissemination of the virus within a specific
region as well as along migratory pathways (Hoogstraal et al., 1961; Zeller
et al., 1994).
As seen in Figure 1.3, Hyalomma ticks are present across all of Africa and
a large portion of Europe and Asia. It has also been hypothesised that future
climate change may increase the range of Hyalomma ticks, thus increasing
the number of people who are at risk of CCHFV infection (Purnak et al.,
2007).




Human infection has a case fatality rate of up to 40 % (Bente et al., 2013),
with infection most often occurs through the bite of a tick carrying the virus,
or through contact with the tissue or blood of an infected patient or animal.
For transmission to occur from infected blood, it must come into contact
with an open wound or mucous membrane. The majority of CCHF cases in
South Africa occur in the North West Province, Free State, and Northern and
Western Cape (Horak et al., 2002). In a large portion of the cases, infection
occurs in individuals who are involved in the livestock industry as well as
people who visit rural areas (Swanepoel et al., 1989, 1983). An important fact
to consider is that for humans to become infected, they do not have to be
bitten by an infected tick; simply squashing the tick and coming into contact
with their blood has been shown to cause infection. The virus can gain entry
through small wounds on the hands or through mucous membranes such as
the eyes (Hoogstraal, 1979).
Between 1981 and 2006, only 180 cases of CCHF have been diagnosed.
In comparison to the serological evidence that the disease in livestock is
widespread (Swanepoel, 1996), the prevalence of CCHF in human populations
is low, even among high risk individuals. There are two possible explanations
for this: first, that the majority of cases are asymptomatic and thus go un-
diagnosed. This, however, is unlikely as serological surveys of rural residents
showed a low prevalence of CCHF antibodies in the population (Fisher-Hoch
et al., 1992), discrediting this theory. The current explanations for low CCHF
incidence in humans is that humans are not the preferred host for Hyalomma
ticks, as well as the fact that the viraemia in livestock is comparatively low
and short-lived when compared to other zoonotic viruses that are more readily
acquired from infected tissue, such as Rift Valley fever virus (Swanepoel et al.,
1987).
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1.1.5 Clinical progression and diagnosis of human infec-
tion
As seen in Figure 1.4, the progression of CCHFV infection has 4 clinically
distinct phases. These are the following:
1. The incubation phase, before the onset of symptoms, can last between
3 and 7 days.
2. The pre-haemorrhagic stage, classically characterised by a sudden onset
of fever, headaches, myalgia and dizziness has been reported to last
anything from 1 to 7 days. This large difference is possibly due to
several factors, such as viral load and route of exposure. Diarrhoea,
nausea and vomiting have also been reported in some cases.
3. The haemorrhagic stage is characterised by the onset of haemorrhagic
symptoms. There is a large range in the severity of haemorrhagic symp-
toms, from mild petechial to large haematomas on the skin mucus
membranes of the patient. There are also reports of bleeding from a
range of other sites, including the nose, the intestines, the uterus and
the urinary tract (Ergönül, 2006).
4. Patients that go on to recover generally show improvements by the
ninth day of illness although symptoms such as light confusion, and
amnesia can continue for a month or more (Swanepoel et al., 1989).
Other symptoms of the convalescent stage include temporary loss of
hair, difficulty in breathing and loss of both vision and hearing.
Diagnosis of CCHFV infection is dependent on the stage that the patient
is in (Figure 1.4). During the initial stage of the infection, a PCR-based
detection method is used, normally with primers targeting the S segment of
the virus. The detection of antibodies against the virus (both IgM and IgG)
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usually coincides with the onset of haemorrhagic symptoms (Vanhomwegen
et al., 2012). The presence of antibodies is clinically significant as it has been
shown to be an important marker for survivability of the infection. Patients
who do not mount an antibody response to the infection by 7 days have a
low survival rate (Swanepoel et al., 1989).
Antibody based detection of CCHFV at one stage required BSL4 contain-
ment (Vanhomwegen et al., 2012), as whole lysed virus-infected cells were the
only source of antigen. This significantly increased the costs of the assay, as
well as the time that it takes to perform. However, recently work has been
done to produce recombinant CCHFV NP for use in ELISAs for diagnostics.
(Samudzi et al., 2012).
The NP is an ideal diagnostic antigen, because it is the most abundant
protein produced by the virus. As the protein is housed inside the viral particle,
it is also a useful marker for viral clearing, as intact virus particle would not
elicit a NP antibody response. The NP is also highly conserved across CCHFV
virus strains (Deyde et al., 2006), allowing for improved detection of infection
across a range of samples.
CCHFV NP has previously been expressed in insect (Zhou et al., 2011)
and bacterial (Samudzi et al., 2012) cell culture. Insect cell culture has the
drawback of high cost as well as the difficulty of producing and maintaining
the required baculovirus clones (Saijo et al., 2002). Bacterial expression of
CCHFV NP leads to insoluble protein being produced. This increased the
downstream processing requirements, increasing the cost and time required to
produce a protein ready for use in a diagnostic assay (Samudzi et al., 2012).
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Figure 1.4: Clinical and laboratory, diagnostic course of a CCHFV infection
(Bente et al., 2013).
1.1.6 CCHFV treatment
Treatment for CCHFV is mostly supportive, based on the symptoms of the
patient. Fluid or whole blood replacement are common therapies to counter-
act the drop in blood pressure due to blood loss. In the past, early treatment
with Ribavirin, an anti-vral drug, has been shown to be effective (Khan et al.,
2003) although a more recent, blinded study has failed to show any thera-
peutic benefit when compared to supportive treatment (Koksal et al., 2010).
Antibody based treatments have also been used, with limited documented
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success. There is anecdotal evidence that treatment with hyperimmune serum
from recovering CCHFV infected patients causes transient improvement of
symptoms, however there has been no blinded clinical trial on the method
(Bente et al., 2013).
1.1.7 Vaccination
In the 1970s, a formalin-inactivated, mouse brain-passaged CCHFV vac-
cine was developed and approved for use in the Soviet Union. A similar vaccine
is currently in use in Bulgaria where it is given to high-risk individuals, such
as soldiers and healthcare workers in endemic regions. There has however
been no clinical trial conducted using this vaccine and serological studies of
vaccinated individuals show a low level of neutralising antibodies produced.
The only evidence for the vaccine’s efficacy is based on the historical num-
bers of CCHFV infections before and after vaccination was introduced (1100
and 279, respectively). There has been little modern work on producing a
CCHFV vaccine, mostly due to the lack of, until recently, an animal model to
test the vaccine in. One group evaluated a multivalent DNA vaccine against
the similar bunyavirus disease agents causing Rift Valley fever, tick-borne
encephalitis, Hantaan River Virus and CCHFV, but it was shown to be only
weakly antigenic in mice (Spik et al., 2006). Another study involved feeding
mice transgenic tobacco plants expressing the CCHFV glycoproteins. The
mice were shown to mount an antibody response to the glycoproteins, but no
work was done to show neutralization (Ghiasi et al., 2011).
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1.2 Plant-based protein expression
1.2.1 Introduction
Using plant cells as a platform for expressing recombinant proteins, either
in cell culture or as part of a whole plant tissue, has been an area of interest
since the late 1980s with the production of the first functional antibody in
transgenic plants (Hiatt et al., 1989) and the early 1990s with the production
of the first virus-like particle (VLP) in plants (Mason et al., 1992). Since
then, there have been numerous changes and improvements in the field, from
the movement away from stable transgenic plants to the use of deconstructed
viral vectors for transient expression (Rybicki, 2014).
Proteins produced in plant-based expression systems have the advantages
of being human pathogen-free as well as of containing post-translational
modifications including glycosylation. Recent work has been performed on
humanising the glycosylation patterns of proteins that Nicotiana benthami-
ana produces by transiently expressing the cellular machinery required for
mammalian O-glycosylation and N-glycosylation (Yang et al., 2012).
1.2.2 Transgenic plants
Traditionally, expressing any protein in plants required the lengthy process
of creating stable, nuclear- transformed, transgenic plant lines. Produced by
using either Agrobacterium-mediated gene transfer (Deblaere et al., 1985) or
by particle bombardment (Kikkert et al., 2005), these processes can take 2-4
months to produce recombinant proteins in Nicotiana tabacum and there
is no guarantee that after that time the transgenic plant will express the
recombinant protein. The other main limitation of nuclear transformation is
the low yields of many proteins expressed using this method (Fischer et al.,
2004).
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To address the issue of low expression, research was done into transform-
ing the chloroplast of the host plant. There are several advantages to this
method: the full chloroplast genomes of many plant species have been se-
quenced, allowing for prediction of gene regulation once inserted; chloroplasts
are maternally inherited, so containment of the foreign gene is easier; chloro-
plasts are also capable of accumulating large amounts of protein - up to 46 %
TSP in stably transformed lines (Verma and Daniell, 2007). However, the
long timescales required to generate transgenic plants are also present when
performing chloroplast transformation. The desire for a system that can be
evaluated in days, rather than months, lead researchers to focus their efforts
on transient expression in plants. This focus has made transient plant ex-
pression a viable alternative to both nuclear and chloroplast transgenic plant
expression (Rybicki, 2010).
1.2.3 Transient expression
Transient expression systems have allowed for rapid expression of pro-
teins at higher levels of TSP than when nuclear transformation is performed
(Daniell et al., 2009). Recombinant expression vectors can be introduced
into the host cells using a process called agroinfiltration. This is achieved
by vacuum infiltrating the host plant with a suspension of Agrobacterium
tumefaciens, harbouring the recombinant expression vector of choice.
The expression vectors used are either simply Agrobacterium-derived plas-
mids, with the expression cassette inserted in the Agrobacterium T-DNA, or
can include viral gene regulation elements, as well as functional elements,
such as movement and replication proteins. The plant virus vectors that are
currently in use are derived from Tobacco mosaic virus (TMV) (Marillonnet
et al., 2004), Cauliflower Mosaic Virus (CMV) (Sainsbury and Thuenemann,
2009) and more recently Bean-Yellow Dwarf Virus (BeYDV) (Regnard et al.,
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2010), among others.
Transiently expressed plant produced proteins are also not limited to the
laboratory. Several proteins have been produced in GMP-certified facilities
for use as human pharmaceuticals. Medicago Inc. have produced a pandemic
influenza VLP vaccine (Vicente et al., 2011; D’Aoust et al., 2008) and the
Fraunhofer USA Institute have produced an influenza vaccine based on the
haemagglutinin subunit (Shoji et al., 2011). Both of these vaccines have com-
pleted phase I human clinical trials (Fischer et al., 2012). A plant-produced
pharmaceutical that has held considerable public interest recently is ZMapp;
this is a cocktail of three monoclonal antibodies, produced by LeafBio Inc.,
that is used as a treatment for Ebola virus disease. The antibodies are pro-
duced in N. benthaniama using both a TMV-based and PVX-based vector
system and have recently been shown to induce full protection against a lethal
viral challenge in non-human primates (Qiu et al., 2014).
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1.3 Project aims and outline
Detection of CCHFV antibodies is currently expensive and hazardous,
due to the need for live virus-infected tissue-culture and the associated BSL4
containment required for working with the cells and all resulting products. The
aim of this work was to produce a CCHFV nucleocapsid protein (NP) for use
in diagnostics, using a plant-based transient expression system to improve the
safety as well as decrease the cost associated with using traditional diagnostic
reagents. The approach included the following:
• Synthesis of the CCHFV NP gene and cloning into three different ex-
pression vectors in order to compare NP expression levels after Agrobac-
terium-mediated infiltration with the 3 different constructs. This in-
cluded comparisons of NP expression when Agrobacterium constructs
were co-infiltrated with a silencing suppressor as well as the comparison
of NP expression levels after harvesting at different time periods post
infiltration.
• Selection of the construct and conditions at which the highest levels of
protein were expressed and the subsequent development of a purification
protocol of NP in order to purify it.
• Testing of the ability of the plant-produced NP protein to be used as
a diagnostic reagent to detect anti-CCHFV antibodies in serum from
individuals previously infected with CCHFV.
Expression of Crimean-Congo haem-
orrhagic fever virus nucleocapsid
protein in Nicotiana benthamiana
2.1 Introduction
The Crimean-Congo haemorrhagic fever virus (CCHFV) nucleocapsid
protein (NP) is encoded for on the S segment of the virus genome and is an
important antigen used for the diagnosis of CCHFV infection (Bente et al.,
2013). Human and veterinary surveillance is an important part of monitoring
and predicting potential outbreaks of the virus. Thus there is a great need
for a specific, sensitive and cheap assay for infection that can be deployed
across Africa, Asia and Russia.
Plant cells contain a defence system against viral infection, termed post-
translational gene silencing. This can decrease yields of recombinant proteins
expressed in plants. To counter this, a gene-silencing suppressor, such as the
NSs protein from tomato spotted wilt virus (Prins et al., 1996), is often co-
expressed with the protein of interest. This has been shown to increase the
overall yield of recombinant proteins harvested from N. benthaniama leaves
(Maclean et al., 2007).
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To facilitate detection and purification of recombinant proteins, affinity
tags are often added to the sequence of the protein of interest. The polyhis-
tidine tag is often used in recombinant protein expression as it has several
desirable properties: small size (0.84 kDa), low immunogenicity, minimal effect
on protein function and the availability of high quality detection antibodies
(Young et al., 2012). Combined with the ease and flexibility of purification
that it allows, this makes the polyhistidine tag an ideal affinity tag.
In this chapter, I will discuss the expression optimisation of Crimean-
Congo haemorrhagic fever virus nucleocapsid protein (NP) in N. benthamiana.
Selecting the best combination of expression time and vector used as well
as the inclusion of a RNA silencing suppressor resulted in a high level of
expression, essential for further work on purification and characterisation.
The cloning and expression of CCHFV NP reported in this chapter lays
the groundwork for further work in bulk expression and purification of NP as
well as serology using the NP as a capture antigen.
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2.2 Materials and methods
2.2.1 Codon optimisation of the NP gene
The coding sequence of the CCHFV isolate SPU 431/85 S segment en-
coding the NP gene (GenBank: DQ211648.1) was submitted to GenScript
Inc. (USA) for Nicotiana sp. codon optimisation and gene synthesis. Codon
optimisation was performed using OptimumGeneTM by Genscript Inc. The
following parameters were optimised for N. tabacum:
• Codon usage bias
• GC content




The CCHFV S segment (GenBank: DQ211648.1) was synthesised as a
single gene by GenScript Inc. (USA) and cloned into pUC57-Kan (GenScript
Inc. USA) (Figure 2.1) using the blunt cutting EcoRI site. This was designated
pUC57-N.
2.2.3 Plant expression vectors
The plant expression vectors pTRAc-HT (provided by Rainer Fischer of
the Fraunhofer Institute for Molecular Biology and Applied Ecology, IME, Ger-
many), pRIC-3.0-HT (Regnard et al., 2010), and pEAQ-HT (Prof G Lomonos-
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soff at the John Innes Centre, Norwich and Plant Biosciences Limited, Nor-
wich) were used in this study.
Figure 2.1: pUC57-N - The vector includes a lacZ -alpha site for blue/white
cloning selection and an aminoglycoside phosphotransferase (KanR) gene to
confer resistance to kanamycin. The NP gene is cloned into the single EcoRI
site.
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A summary of all of the vectors and their antibiotic resistance markers
used in this study can be found below in Table 2.1.
Table 2.1: Plasmids used in this study
Plasmid Antibiotic and working concentration
pUC57-N Kanamycin, 50 µg/ml
pRIC 3.0-HT Ampicillin, 100 µg/ml
pTRAc-HT Ampicillin, 100 µg/ml
pEAQ-HT Kanamycin, 50 µg/ml
2.2.4 Cloning strategy
The coding sequence for NP was cloned into pTRAc-HT, pRIC 3.0-HT
and pEAQ-HT. For all of the expression vectors, a C-terminal polyhistidine
tag was desirable and already present in the vector. The correct restriction
enzyme sites were included on the 5’ and 3’ termini of the synthesised NP
sequence to allow for direct cloning from pUC57-N into the various expression
vectors. This process is shown in 2.2. Briefly, pTRAc-HT, pRIC 3.0-HT and
pEAQ-HT and pUC57-N were isolated from single colonies grown on the
appropriate selective media, using a QIAGEN Miniprep Kit (Qiagen, USA)
as per the manufacturer’s instructions. The plasmids were then digested using
the appropriate restriction enzymes (see Figure 2.2) and ligated overnight at
4 ◦C using T4 ligase (Roche). The ligated DNA was transformed into chemi-
cally competent DH5α E. coli (E. cloni R©, Lucigen) as per the manufacturers
instructions and the resulting transformants were screened by colony PCR us-
ing either specific primers (Table 2.2) or restriction enzyme digests to confirm
successful cloning.
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Table 2.2: List of Primers used in this study.
Primer Name Sequence Tm (◦C) Description
pEAQ Forward 5’ GACGAACTTGGAG
AAAGATTGTTAAGC 3’
61,9 Vector-specific primer for
use in PCR screening and se-
quencing.
pEAQ Reverse 5’ GACCGCTCACCAA
ACATAGAAATG 3’
61,6 Vector-specific primer for
use in PCR screening and se-
quencing.
pTRAc Forward 5’ CATTTCATTTGGA
GAGGACACG 3’
61,3 Vector-specific primer for
use in PCR screening and se-
quencing.
pTRAc Reverse 5’ GAACTACTCACACAT
TATTCTGG 3’
61,0 Vector-specific primer for
use in PCR screening and se-
quencing.
pICH31070 Forward 5’ CCTCACCCATCTTTT
ATTAC 3’
58,4 Vector-specific primer for
use in PCR screening and se-
quencing.
pICH31070 Reverse 5’ ACACCGTAAGTC
TATCTC 3’
57,1 Vector-specific primer for
use in PCR screening and se-
quencing.
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pEAQ-N (HT) cloning pTRAc-N (HT) cloning
pRIC-N (HT) cloning
Fig 2.2a Fig 2.2b
Fig 2.2c
Figure 2.2: Cloning strategy for expression of NP. (a) XmaI and XhoI were
used to clone NP into pEAQ- HT as well as including an in frame C-terminal
his-tag. (b+c) NcoI and XhoI were used to clone NP into pTRAc-HT(b) and
pRIC 3.0-HT(c) as well as including an in frame C-terminal his-tag.
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2.2.5 A. tumefaciens transformation
A. tumefaciens transformation was performed by electroporation. The
electrocompetent cells were prepared as previously described (Shen and Forde,
1989). The A. tumefaciens GV3101::pMP90RK was used for pRIC3.0-HT and
pTRAc-HT constructs and the strain LBA4044 was used for pEAQ-HT con-
structs. Transformation was performed by mixing 100ul of electrocompetent
cells with 500ng of plasmid DNA in a 1mm gap electroporation cuvette. Elec-
troporation was performed at 1.8kV, 25mF, 200Ω with a Bio-Rad GenePulser
(Bio-Rad Laboratories, USA). The cells were incubated in Lysogeny broth
(LB) broth for 2 hours at 27 ◦C and then plated on the LB agar (LBA) plates
containing the relevant selective antibiotics (Table 2.3). The plates were then
incubated at 27 ◦C for 48h. Resulting single colonies were picked and grown
in LB broth with the appropriate antibiotics for 48h. Plasmid was isolated
using a QIAGEN Miniprep Kit (Qiagen, USA) as per the manufacturer’s
instructions and transformed back into competent DH5α E. coli (E. cloni R©,
Lucigen) to confirm successful transformation of the A. tumefaciens with the
expression plasmid.
Table 2.3: A. tumefaciens strains used in this study
A. tumefaciens strain Plasmids used Antibiotic Selection Notes
GV3101::pMP90RK
pRIC 3.0-HT 30 µg kanamycin
pTRAc-HT 50 µg carbenicillin
50 µg rifampicin
LBA4044
pEAQ-HT 30 µg kanamycin
2 mM MgSO4 to prevent cell clumping
pBIN-NSs 50 µg rifampicin
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2.2.6 Agroinfiltration ofN. benthamiana leaves for small-
scale transient protein expression trials
A single, freshly streaked colony of the appropriate A. tumefaciens strain
was inoculated into 10ml of LB media containing the appropriate antibiotics
(Table 2.3) and incubated with shaking at 150rpm at 27 ◦C for 24h. The
resulting culture was then diluted into 50ml of induction medium (LB broth
with 10 mM MES, 2 mM MgCl2, 1 mM acetosyringone, pH 5.6) to obtain
an OD600 of 0.1 and then incubated with shaking at 150rpm at 27 ◦C for 24h.
The culture was centrifuged for 10 minutes at 4000 x g at 4 ◦C to pellet the
A. tumefaciens cells. The cells were then resuspended in infiltration medium
(3 % (w/v) sucrose, 10 mM acetosyringone, 10 mM MES, 2 mM MgCl2, pH
5.6). The culture was diluted to the appropriate OD600 for infiltration (Table
2.4) and allowed to incubate at room temperature for 2 hours to induce the
vir genes. Six to 8 week old N. benthamiana plants were infiltrated with the A.
tumefaciens suspension by injection in to the abaxial airspaces of the ventral
side of the leaves using a needleless syringe.
Table 2.4: Dilution of cultures for A. tumefaciens small-scale infiltration
trials.
A. tumefaciens strain Plasmid OD600
GV3101::pMP90RK
pRIC-N (HT) 0,25; 0,5; 1,0
pTRA-N(HT) 0,25; 0,5; 1,0
LBA4404
pEAQ-N(HT) 0,25; 0,5; 1,0
pBIN-NSs 0,25
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2.2.7 Small-scale protein extraction
Three leaf-disks were harvested from 3 different plants, using the cap of
a 1.5ml microcentrifuge tube (each disk weighing approximately-10mg) and
immediately flash-frozen and ground into a fine powder using liquid nitrogen
in a mortal and pestle. The different plants were all of a similar age and
efforts were made to ensure that similar age leaves were used for each data
point. Three hundred µl of PBS was added to resuspend the leaf powder. The
resulting extract was centrifuged at 13000 x g for 10 min at 4 ◦C to pellet the
insoluble material. The extract was immediately prepared for SDS-Page by
the addition of 5 x SDS sample buffer (25 % (v/v) glycerol, 0.5 M DTT, 5 %
(w/v) SDS, 0.001 % (w/v) bromothymol blue) and incubation at 95 ◦C for 5
minutes. The protein sample was either used immediately or frozen at -20 ◦C.
2.2.8 Protein electrophoresis
Proteins in prepared samples were separated by SDS-Page (Sambrook and
Russell, 2006). Ten-percent SDS-polyacrylamide gels were cast and run us-
ing the Biorad Mini-PROTEAN R© Tetra Cell Systems (Bio-Rad Laboratories,
USA) at a constant voltage of 125V as per the manufacturer’s instructions. All
gels were loaded with constant volumes of protein extract and the PageRuler
pre-stained protein ladder SM6071 (Fermentas, Canada) was used as a molec-
ular weight standard.
2.2.9 Western blotting
The electrophoresed protein was transferred to a nitrocellulose membrane
(Hybond ECL, GE Healthcare, USA) using a Bio-Rad Trans-Blot R© Semi-dry
transfer blotter at 15V for 90 minutes. The membrane was then blocked using
blocking buffer (5 % skim milk powder in PBST) for 30 minutes at room
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temperature. Primary antibody (anti-6x His tag antibody, Abcam [HIS.H8])
was diluted as appropriate (1/2000) in blocking buffer and incubated at
4 ◦C for 16h, a NP-specific antibody was not available. The membrane was
then washed 4 x 15 minutes in blocking buffer. Diluted secondary antibody
conjugated to alkaline phosphatase was incubated on the membrane for 1
hour at 37 ◦C. The membrane was finally washed for 4 x 15 minutes in PBST





Codon optimisation of the NP for expression in Nicotiana benthamiana
was successfully carried out. The Codon Adaptation Index (CAI) was im-
proved from 0,73 to 0,87 (Figure 2.3a), Frequency of Optimal Codons (FOP)
was shifted so that 64 % of the codons fell within the highest usage frequency
of N. benthamiana (2.3b) and finally the GC content of the gene was reduced
from 47.72 % down to 40.4 % to bring it in to line with the GC content of the
Nicotiana sp. genome GC content (2.3c).
Several internal restriction enzyme sites that would have interfered with
subcloning were also removed from the sequence, along with 3 different cis-
acting elements (PolyA(AATGAA); PolyA(AATGGA) and PolyA(AAAAAAA)).
The final gene sequence, aligned with the original sequence is presented in
Figure 2.4.
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1.  Codon usage bias adjustment
Figure 1a. The distribution of codon usage frequency along the length of the gene sequence.  A CAI of 1.0 is considered to be 
perfect in the desired expression organism, and a CAI of > 0.8 is regarded as good, in terms of high gene expression level.
 CAI:
  After OptimumGeneTM Optimization
Codon Adaptation Index (CAI)
Figure 1b. The percentage distribution of codons in computed codon quality groups.  The value of 100 is set for the codon with the
highest usage frequency for a given amino acid in the desired expression organism. 
Figure 2. The ideal percentage range of GC content is between              %. Peaks of %GC content in a 60 bp window have been
removed.
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Figure 2.3: Codon and GC content optimisation f the NP gene. a) The
distribution of codon usage frequency along the length of the gene sequence.
A CAI of 1.0 is considered to be perfect in the desired expression organism,
and a CAI of > 0.8 is regarded as good, in terms of high gene expression level.
b) The percentage distribution of codons in computed codon quality groups.
The value of 100 is set for the codon with the highest usage frequency for a
given amino acid in the desired expression organism. c) The ideal percentage
range of GC content lies between 30 % and 70 %. Peaks of GC content in a
60 base pair window have been removed.
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Figure 2.4: Alignment of codon optimised NP nucleotide sequence (NP (op-
timised)) with the wildtype (NP (unoptimised)) NP gene sequence (GenBank:
DQ211648.1). The unoptimised gene is shown on the left and the optimised
gene is shown on the right.
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2.3.2 Cloning
NP was sub-cloned directly into pRIC 3.0, pTRAc-HT and pEAQ-HT
using the required restriction enzyme sites to include a C-terminal 6xhis-tag.
Successful cloning was confirmed using restriction enzyme digests (Figure 2.5)
and sequencing (not shown).







899 bp 883 bp
6000
Figure 2.5: Restriction enzyme digests (XbaI) of recombinant expression
constructs: (1) GeneRuler 1Kb DNA ladder (2) pTRAc-N(HT), (3) pRIC-N




Once the expression vectors were successfully transformed into A. tume-
faciens and confirmed as described in the section 2.2.5, an expression trial
was set up to compare the expression of NP over the course of 7 days, the
effect of different concentrations of Agrobacterium (Table 2.4), as well as the
effect of co-infiltration of a post translational silencing suppressor with the
pRIC and pTRAc clones, in this case pBIN-NSs (Prins et al., 1996). The
pEAQ-HT vector contains its own p19 silencing suppressor (Sainsbury and
Thuenemann, 2009) gene, so co-infiltration with pBIN-NSs was not necessary
when infiltrating with pEAQ-N(HT).
Initial trials showed that NP was expressed at its highest yield at an OD600
of 1.0 across all 3 vectors (data not shown). Subsequently all trials were done
at an OD600 of 1.0.
Levels of NP in crude leaf extracts were assessed qualitatively by western
blotting. NP was detected as a 55kDa sized protein using anti-6 x His tag
antibody (Abcam, USA) (Figure 2.6 - lanes depicted as -). Leaves infiltrated
with pRIC-N(HT) showed the expression of NP from day 1 through to day
7 post infiltration with the highest protein yield being observed on day 3
(Figure 2.6a). Leaves infiltrated with pTRAc-N(HT) showed peak expression
of NP occurring from day 3 through to day 5 post infiltration (2.6b) Prior
to day 3 and after day 5, expression yields decreased. Leaves infiltrated with
only infiltration buffer showed no expression.
With regard to the barely discernible NP expression using pEAQ-N(HT),
the culture used for infiltration was subsequently screened to determine
whether the NP gene or the entire construct had perhaps been ejected from
the Agrobacterium cells. However, it was confirmed that pEAQ-N(HT) was
present in the A. tumefaciens used to infiltrate the plants, using back transfor-
mation and restriction enzyme digests (not shown) and therefore concluded
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that the barely detectable presence of NP protein was due to low expression














Figure 2.6: Expression time-trial of a) pRIC-N(HT), b) pTRAc-N (HT) and
c) pEAQ-N (HT). (+) and (-) indicate samples infiltrated with and without
NSs respectively. (-ve) represents samples infiltrated with infiltration buffer
only.
Expression yields of NP in crude leaf extracts from leaves infiltrated with
pRIC-N(HT) or pTRAc-N(HT) only (Figure 2.6 a and b, lanes depicted as -)
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were compared when these were co-infiltrated with the pBIN-NSs silencing
suppressor construct (Prins et al., 1996) (Figure 2.6 a and b, Lanes depicted
as +).
Higher yields of NP were detected using pRIC-N(HT) when the construct
was co-infiltrated with the silencing suppressor, particularly at days 3 and 5
post infiltration (Figure 2.7a). Co-infiltration of the silencing suppressor with
pTRAc-N(HT) did not appear to qualitatively increase or decrease expression
of NP (Figure 2.7b). In order to distinguish which of these two constructs to
select for scaling up of NP production and subsequent purification, a further
small-scale expression experiment incorporating parameters which resulted in
the four highest levels was carried out to determine the optimum expression
conditions. These were: infiltration of pTRAc-N(HT) at days 3 and 5 post
infiltration with no silencing suppressor and pRIC-N(HT) at days 3 and 5 post
infiltration with the silencing suppressor (Figure 2.6). Western blot results of
this experiment are shown in Figure 2.7.
Crude leaf extracts pRIC-N(HT) co-infiltrated with the silencing suppres-
sor and sampled at 3 days post infiltration produced the darkest bands on a
western blot, suggesting that this combination of constructs and these condi-
tions are optimal for recombinant NP expression. This construct was therefore
selected for the scaled-up production and purification of NP.
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Figure 2.7: Comparison of expression between pRIC-N (HT) and pTRAc-N
(HT) on day 3 and 5, with (+) and without (-) pBIN-NSs.
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2.4 Discussion
A. tumefaciens mediated transient expression in N. benthamiana is an
extremely fast and efficient method for evaluating the expression of novel
proteins in plants. It has been shown to result in superior expression yields
when compared to yields of recombinant protein expressed in transgenic plants
(Rybicki et al., 2012).
Codon optimisation and synthesis of NP allowed for the gene to be rapidly
cloned into the three expression vectors tested, cutting out the intermediate
PCR steps that are required to add the correct restriction enzyme sites to a
cDNA clone or any other natural DNA source. Coupled with the rapid, tran-
sient expression, this allowed us to rapidly determine the optimal expression
conditions under which to conduct Agrobacterium-mediated infiltration in
order to obtain maximal recombinant NP yields prior to continuing with scal-
ing up production and purification and analysis of NP. Unfortunately, there
was no reference standard available to quantify the amount of NP expressed
in N. benthamiana. Comparisons of expressed NP yields by western blotting
showed that while pRIC-N(HT) and pTRAc-N(HT) showed expression over
a period of 1 to 7 days, pEAQ-N (HT) showed very low expression yields in
comparison to pRIC-N(HT) and pTRAc-N(HT). Low protein expression is a
complex problem, often driven by a variety of factors (Duong-Ly and Gabelli,
2014). As expression was achieved using the pRIC 3.0 and pTRAc vectors,
optimisation of a pEAQ based expression system was abandoned. The ex-
pression vectors pTRAc-HT and pRIC 3.0-HT both make use of a modified
Cauliflower mosaic virus (CaMV) 35S promoter to drive expression of the
recombinant gene (Maclean et al., 2007). pRIC 3.0-HT has however been
modified to include Bean yellow dwarf virus (BeYDV) replicating machinery
in cis. This allows for many, replicating copies of the gene of interest to be
produced, which also increases the mRNA levels of the gene present in the
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cell (Regnard et al., 2010).
pBIN-NSs is derived from the S-segment of tomato spotted wilt virus
(TMSV). pBIN-NSs acts by suppressing the gene silencing machinery of
the host plant, in this case, N. benthamiana (Prins et al., 1996). In this
study, we saw that inclusion of pBIN-NSs with pRIC-N(HT) allowed increased
expression, but with pTRAc-N(HT) there appeared to be more expression
when it was not included. This is most likely due to the host gene silencing
machinery not being activated when pTRAc-N(HT) was used, due to the low
copy number present in each cell, and it was likely detrimental to expression,
because the cell’s gene expression organelles, proteins and RNA had to be
split between the expression of N and NSs. However, with pRIC-N (HT),
the high levels of mRNA present in the cells may have induced a host gene
silencing response, hence the increased expression yields seen when pBIN-
NSs was included with pRIC-N(HT). The expression across both vectors, was
however low, especially when compared to other proteins previously expressed
using these vectors (Maclean et al., 2007; Regnard et al., 2010) In both cases,
very little, to no signs of necrosis or physiological stress were observed on
the leaves of infiltrated plants. At 3 days post infiltration, it was difficult to
visually differentiate between plants infiltrated with the construct and plants
infiltrated with only infiltration medium. This indicates that the protein is
either does not effect the plans physiology, or is expressed in a concentration
that is too low to effect the plants physiology.
In work done for this chapter, 3 different plant expression vectors were
tested for their ability to express CCHFV NP with only two showing any
meaningful levels of expression as detected by western blotting. Of the two
that showed meaningful expression yield, there was a noticeable difference in
the NP yields, showing that when expressing proteins in plants, it is best to test
several different expression vectors when determining the optimal expression
conditions. NP was successfully expressed and parameters established under
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which to obtain the highest levels in N. benthamiana leaves as determined
by comparative western blots. This enabled us to identify the recombinant
constructs with which to continue working as pRIC-N(HT) and pBIN-NSs
as well as to establish that harvesting of leaves at 3 days post infiltration
was optimal, laying the way for further work on scaling up production and
purification of NP.
Purification of Crimean-Congo haem-
orrhagic fever virus nucleocapsid
protein
3.1 Introduction
Purification of a single protein from a complex host mix of proteins is
often required for further characterisation and use downstream.
There are several strategies for purifying proteins, all of which take ad-
vantage of a certain biochemical characteristic of the protein itself, or a re-
combinant "affinity-purification tag" that has been added to the protein, to
separate it from the complex mix. The general method for this separation is
termed chromatography.
Using an affinity tag has several advantages, such as easy protein detection,
improved solubility and stability, as well as several disadvantages, including
interference with native protein structure and the inability to completely
remove the tag if needed.
Affinity tag purification may also not produce a sufficiently pure protein.
In cases like this, further biochemical methods, such as ion-exchange or gel
filtration can be used to separate the remaining proteins.
46
47
The reliability and efficiency of chromatography can be improved by using
a column-based, automated purification system. This allows for improved
repeatability, as well as ease of scaling up if required.
For both time, cost and purification efficiency reasons, the protein of inter-
est must be present in sufficiently high concentrations before continuing with
the necessary chromatography. If this is not the case, a selective, concentrat-
ing step can be used. An example of this, ammonium sulphate precipitation,
makes use of a proteins’ varying solubility at varying concentrations of salt to
separate these proteins. Ammonium sulphate precipitation can also be used
to concentrate a protein sample after chromatography, such as gel filtration.
In this chapter, the purification of Crimean-Congo haemorrhagic fever
virus nucleocapsid protein (NP) from a complex mix of host plant proteins,
to a sufficient purity for further use and characterisation is described. Using
a combination of precipitation and affinity tag purification coupled with an
automated column chromatography system (ÄKTA Explorer, GE Healthcare),
allowed for rapid, cost effective and scalable purification.
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3.2 Materials and methods
3.2.1 Large-scale Agroinfiltration of N. benthamiana
Day 1: Pre-cultures of recombinant A. tumefaciens harbouring pRIC-
N(HT) and pBIN-NSs were started by inoculating 5ml of YEB medium (per/L:
beef extract; 5g; yeast extract: 1g; peptone: 5g sucrose: 5g; MgSO4: 300 mg),
containing the appropriate antibiotics (Table 2.3), from freshly streaked LBA
plates of the respective Agrobacterium hosts. The cultures were incubated at
27 ◦C for 16h.
Days 2 and 3: The entire pre-cultures were inoculated into 250ml of
YEB medium, containing the appropriate antibiotics but excluding rifampicin.
These cultures were grown at 27 ◦C for 40h.
Day 4: The OD600 values of the cultures were determined and were subse-
quently diluted to an OD600 of 1.0 for pRIC-N (HT) and 0.25 for pBIN-NSs,
using 2 x infiltration medium (per/L: sucrose: 100g; glucose: 3,6g; Ferty-2-
Mega: 1g; pH 5.6). Acetosyringone was added to a final concentration of
200 µM.
Twenty 6 to 8 week oldN. benthamiana plants were vacuum-agroinfiltrated
by submerging whole plants in the infiltration medium, applying a vacuum
of −90 Pa and quickly releasing the vacuum. The plants were then grown
under conditions of a 16:8 hour light:dark cycle, a temperature of 24 ◦C and
humidity of 55 % until ready for harvest (3 days post infiltration).
3.2.2 Protein extraction
Three days post infiltration the infiltrated leaves were harvested, weighed
and 1 x PBS added at a volume of 3ml/g of leaf material. The mixture was
then homogenised on ice until a uniform consistency was achieved and then
incubated at 4 ◦C for 1h.
49
The extract was maintained at 4 ◦C for all subsequent steps.
The extract was clarified by first filtering through MiraclothTM (22-24µm
pore, Millipore, USA) and then centrifugation at 10 000 x g for 20 min was
performed. This was repeated 3 times, retaining the supernatant at each step.
Finally, 0.02 % sodium azide was added to inhibit bacterial growth. The
extract was either further purified immediately or stored at 4 ◦C until purifi-
cation could be performed.
3.2.3 Ammonium sulphate precipitation
Precipitation was performed by adding solid ammonium sulphate ((NH4)2SO4)
to the protein extract prepared as describe in 3.2.2. The (NH4)2SO4 was added
slowly to the extract and kept at 4 ◦C with constant stirring. The amount
of solid (NH4)2SO4 required was calculated using the online tool available at
http://www.encorbio.com/protocols/AM-SO4.htm. Once the (NH4)2SO4
was added, the extract was left at 4 ◦C for 1 hour, with stirring, to equilibrate
and for the protein to precipitate. Finally, the extract was centrifuged at 10
000 x g for 20 minutes, to pellet the extracted protein. The supernatant was
removed and either discarded, or precipitated using a higher percentage of
(NH4)2SO4, as needed. The pellet was either stored at 4 ◦C, or dissolved in
buffer and used immediately for downstream purification. For bulk precipita-
tion, the 40-80 % fraction was used as it contained the majority of the target
protein (Figure 3.1).
3.2.4 Chromatography
Chromatography was performed using an automated, fast protein liquid
chromatography (FPLC) system (ÄKTAexplorer 100). The system has a
multi-wavelength UV light absorption detector, as well as a conductivity
meter, to aid the purification process.
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FPLC systems have several advantages over manual processing, such as
improved purity and consistency, as well as cost saving (Fichtali et al., 1992).
All samples were filtered through a 0.45 µm polyvinylidene fluoride (PVDF)
syringe filter to ensure no particulate matter was present, which would inter-
fere with or damage the chromatography matrix.
3.2.5 Nickel affinity chromatography
Nickel affinity chromatography was performed using a 1ml HisTrap HP
pre-packed column (GE Healthcare, USA). The buffer flow rate throughout
was set at 1ml/min. The column was equilibrated with 10 column volumes
of 500mM NaCL PBS (standard 1 x PBS supplemented with NaCl to a final
concentration of 500mM), supplemented with 20mM imidazole (Buffer A).
Protein sample was injected directly onto the column using a 50ml SuperLoop
and washed with 20 column volumes of buffer A. The protein was eluted using
a linear gradient of imidazole (expressed as a percentage of Elution Buffer)
from 20mM - 500mM. All eluting fractions were collected in 0.5mL aliquots
and stored at 4 ◦C.
3.2.6 Protein quantification
Protein quantification was performed using gel densitometry. Serial dilu-
tions of bovine serum albumin (BSA) were separated on a SDS polyacrylamide
gel (see 2.2.8) alongside purified varying volumes of NP. The gel was then
stained using Coomassie Blue. The BSA was used to construct a linear stan-
dard curve of the density, as measured by gel densitometry using a SynGene
reader - GeneTools (version: 3.07.03). The NP sample concentration was cal-
culated by determining the density of the protein band and then derived from
the BSA standard curve.
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3.3 Results
3.3.1 Ammonium sulphate precipitation
The crude extract was precipitated into 8 different fractions as described
in 3.2.3, increasing the concentration of (NH4)2SO4 by 10 % after each step.
The majority of NP was found in the fractions ranging from 40 % to 80 %
(NH4)2SO4 as seen in Figure 3.1 by the presence of the 55 kDa NP band. Bulk
(NH4)2SO4 for further downstream processing was performed by precipitating
the protein and discarding the precipitate obtained between 0 % and 40 %
(NH4)2SO4 and then retaining the protein precipitated using a 40 % and 80 %
(NH4)2SO4 solution.
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Figure 3.1: Western blot of equal volume of the 8 precipitated protein
fractions ranging from 0 to 80 % (NH4)2SO4 separated by SDS-Page. NP was
detected using an anti-6 x his primary mouse antibody.
3.3.2 Nickel affinity
NP was purified successfully using a HisTrap HP pre-packed column. The
elution profile shown in figure 3.2 shows a 280nm protein peak at an elu-
tion volume of 71ml-79ml. Selected fractions from an independent run, on a
Coomassie-stained gel (figure 3.3a) and a cognate western blot probed with
6 x anti-his antibody (figure 3.3b) showed that negligible yields of NP were
detected in the flow through (unbound) fraction (Flow through fraction 2),
as well as in fractions 7 and 8, compared to the yields detected in the sample
originally loaded onto the column (40 - 80 % (NH4)2SO4 precipitation). The
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Coomassie-stained gel (figure 3.3a) shows that the protein was successfully
purified and concentrated to a point that it is the dominant band on the gel at
the expected size (55kDa), with only minor contamination of other proteins
present in the sample. There was also the added advantage of increasing the
concentration of the protein - this can be seen in 3.3a where equal volumes
of sample were added to each lane.
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(a) Overview of NP histidine purification trace









































(b) Expanded view of elution portion of the NP histadine purification trace.
Figure 3.2: Purification traces of NP histidine purification. Produced using





















































































































































































(b) Western blot of histidine purification of NP.
Detected using anti-6his primary mouse antibody.
Figure 3.3: Purification of NP using nickel affinity chromatography. a) Coom-
massie Blue stain and b) Western Blot of various fractions from the nickel
affinity purification of NP.
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3.3.3 Protein quantification
As the sample was not completely pure, testing the total soluble protein
(Using the Bradford Method or similar), would not have given an accurate
indication of the amount of NP present in the purified extract.
Thus, the concentration of NP was calculated from a linear curve generated
by a range of BSA fraction V dilutions of known concentration as described in
section 3.2.6. Once analysed, it was calculated that the final concentration of
purified NP was 0.17mg/ml. This was calculated to be a final yield of 1.6mg
of protein per kg of leaf material harvested. The calculations are summarised
in Table 3.1.











0.17 2.75 296 1.6
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3.4 Discussion
Large-scale vacuum-infiltration is a required step for the agroinfiltration-
based production of any plant-produced protein that requires milligram or
greater quantities for downstream processing.
By incorporating ammonium sulphate precipitation as a first step of pu-
rification, a large number of contaminating proteins were easily and rapidly
removed (data not shown). In addition, this step decreased the working vol-
ume of protein solution, thereby increasing the concentration of NP. This
is important as the decreased volume requires less reagents for subsequent
processing, thus reducing purification costs.
The second stage, nickel affinity chromatography performs a dual function
of further removing a large number of unwanted, contaminating proteins, as
well as concentrating the NP in the final protein solution to be further purified.
The advantages of working with a concentrated protein include flexibility and
ease of handling, as well as improved protein stability. Increased concentration
of the 6 x his-tagged protein has been shown to improve the bind efficiency
of nickel resin columns (Pers. Communication).
The use of an automated, column-based chromatography device, such as
an ÄKTAexplorer, provided a rapid, reliable and most importantly, repeat-
able system for purification of CCHFV NP. An added advantage is that if
required, the purification process can be scaled up by using larger volume
chromatography columns.
In order to determine the feasibility of further scale-up and possibly com-
mercial production of a plant produced protein, the yield of protein is required
to be calculated. This is calculated in mg per kg of leaf material. As discussed
in the previous chapter, this studies expression and subsequent purification
level of 1.6mg/kg is low when compared to other proteins expressed and
purified in plants (Maclean et al., 2007; Duvenage et al., 2013).
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Steps for increasing this expression can include:
• Alternate codon optimisation.
• UTR modification.
• Use of expression vectors based on alternative viral genetics (e.g. Icon
Genetics magnICON R© system).
The purification methods used may also be inefficient. Further work is
required to quantify the losses of expressed protein during purification and to
examine alternate purification systems, such as ion-exchange chromatography,
size-exclusion chromatography or a non-chromoatography based purification
method, such as using elastin-like protein (ELP) as a fusion tag (Duvenage
et al., 2013).
Analysis of the purification showed a significant decrease in the amount
of contaminating protein, although not complete removal.
This purification process was repeated multiple times, across several batches
of infiltrated leaves. Yield and purity, as estimated qualitatively by eye on
both western blots and Coomassie stained gels, was consistent across batches.
The method scaled consistently as the input material was increased (Data
not shown). Potential further work could be to perform a detailed study on
how well the purification scales as the input material increases to the levels
required for commercial production of the protein.
Possibilities for further purification in order to remove the remaining con-
taminating proteins, if needed, include ion-exchange chromatography, which
separates proteins based on their net surface charge; size-exclusion chromatog-
raphy, to separate the proteins based on their globular, in vitro size. A final
option, that would require molecular cloning, would be to add another affinity
tag, such as glutathione S-transferase (GST), which can be purified using a
glutathione-linked chromatography medium. An added advantage to using a
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GST-tag is that it has been shown to increase the solubility and stability of
the protein. The major disadvantage, and why it was not used in this study, is
that the tag is large (220 amino acid residues) and can possibly interfere with
other downstream processing such as further purification, antibody based
detection and proper protein folding.
Detection of CCHFV antibodies in
human serum using plant-produced
NP
4.1 Introduction
Immunological detection of CCHFV-specific antibodies in human serum
requires the use of BSL4 facilities, due to the need for using antigen produced
from tissue-cultured cells harbouring live virus (Vanhomwegen et al., 2012).
Efforts have been made to produce recombinant CCHFV NP in insect cells
(Saijo et al., 2002) as well as bacteria (Samudzi et al., 2012). However, insect
cell-produced proteins are expensive to make and require specialised facilities,
and efforts to express NP in bacteria resulted in issues with low yields and
insolubility.
In Chapter 3 I showed that plant-produced CCHFV NP can be expressed
as a soluble protein with purified yields of up to 1.6 mg of protein per kg
of leaf material, thus potentially providing a safe and cheap alternative to
traditional methods. In this chapter, I describe the work done to test the
immunological specificity of this plant-produced CCHFV NP using an indirect
enzyme linked immunosorbent assay (ELISA) where the NP was used to detect
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IgG antibodies in the serum samples of individuals previously infected with
CCHFV.
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4.2 Materials and methods
4.2.1 Serum samples
All samples were obtained with full informed consent of the donors. Ethics
approval was obtained from the Ethics Committee at the Faculty of Health
Sciences, University of the Free State (Ethics Number 152/06).
Negative panel
Serum samples were obtained from 13 individuals with no known history
of CCHFV exposure. The serum was aliquoted into 2ml Cryotubes (Nalgene
Nunc International, USA) and stored at 4 ◦C for immediate use, or -20 ◦C for
long term storage.
Positive panel
Serum samples from 13 survivors of CCHFV infection collected between
5 and 13 years after illness were available for testing (Table 4.1). All sam-
ples had previously been tested positive for IgG antibody against CCHFV
using indirect immunofluorescent antibody assays (EUROIMMUN) at the
Department of Medical Microbiology and Virology, University of the Free
State (Table 4.1).
Controls
Two known negative and 2 known positive serum samples, previously
verified by Samudzi et al. (2012) were used as negative and positive assay
controls, respectively.
63
Table 4.1: Details of 13 CCHFV positive samples used.
Laboratory Number Patient Identifier Date of Collection Date of onset
2 13 TK 16-Jan-13 28-Nov-09
4 13 HC 24-Jan-13 23-Dec-08
5 13 AS 24-Jan-13 11-Feb-08
6 13 BS 24-Jan-13 07-Nov-00
7 13 JS 24-Jan-13 20-Dec-00
10 13 HD 14-Feb-13 10-Nov-10
13 13 SF 13-Mar-13 17-Mar-08
14 13 GC 13-Mar-13 27-Oct-08
15 13 JB 13-Mar-13 28-May-04
16 13 PB 13-Mar-13 25-Dec-10
19 13 NJ 18-Apr-13 31-Mar-09
20 13 JJ 18-Apr-13 unknown
21 13 WK 18-Apr-13 24-Mar-02
4.2.2 Preparation of mock antigen
Mock antigen was prepared by infiltration of N. benthamiana leaves with
Agrobacterium containing an empty pRIC3.0-HT vector (as described in sec-
tion 3.2.1) and harvesting of leaves after 3 dpi as for pRIC-N(HT)-infiltrated
leaves. The crude extract was subsequently treated using the same NP purifi-
cation protocol outlined in sections 3.2.2, 3.2.3 and 3.2.4, collecting the same
fractions as those collected and pooled from the column.
4.2.3 Indirect Enzyme Linked Immunosorbent Assay (ELISA)
All sample, serum and detecting agent and substrate volumes used were
100 µl, incubations were performed at 37 ◦C and washes with 0.1 % Tween 20
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in phosphate-buffered saline (TPBS) pH 7.0, three times, unless otherwise
mentioned.
Varying dilutions of both antigen and secondary antibody were used to
optimise the assay. All dilutions were prepared in glass vials to minimise
possible interference from protein binding to plasticware.
Purified NP and a mock antigen were coated onto Nunc 96-well PolySorp
plates (Nalge Nunc International, USA) in various dilutions depending on
the application. Coated plates were incubated for 1 hour.
The plates were washed and then blocked and incubated for 1 hour with
10 % skim-milk powder 0.1 % TPBS for 1 hour at 37 ◦C and then washed as
before.
Test serum was diluted 1/100 in 2 % skim-milk powder 0.1 % TPBS, added
to the wells and then incubated for 1 hour at 37 ◦C, followed by a wash step.
Goat anti-human IgG HRPO conjugate (Zymed, USA) was diluted in 2 %
skim-milk powder 0.1 % TPBS, added to the wells and then incubated for 1
hour, followed by a wash step.
ABTS substrate (KPL, USA) was added to each well and the reaction
allowed to proceed for 30 min before absorbance was measured at 405nm and
650nm.
Final absorbance was measured as the difference between 405nm and
620nm to reduce any non-specific background absorbance.
The final value was calculated by subtracting the absorbance of the mock
antigen from the absorbance of the NP to further reduce non-specific back-
ground.
In order to determine the optimum dilution of recombinant NP to coat
the plates with, an antigen titration experiment was set up. Both NP and
the mock antigen were serially diluted, doubling at each step from 1/50 to
1/3200. Two positive and two negative serum samples were used to account
for potential variances in antibody titres between serum samples.
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NP was subsequently used at a dilution of 1/400 for all further indirect
ELISAs to test the remaining sera.
4.2.4 Data analysis
Normalisation of data
To account for background, cross reactivity, from unknown proteins in
capture antigen, net OD is calculated by subtracting the OD reading of the
mock antigen from the OD reading of the NP.
Net optical density (OD):
Net OD = OD in wells with NP minus OD in wells with mock
antigen.
Net OD readings were converted to a percentage of a know high-positive,
in house, control serum , termed Percentage Positivity (PP) as follows:
OD of test sample / OD of know high-positive) x 100 = PP.
Calculating cut-off values
The cut-off value used to separate positive results from negative is calcu-
lated using a panel of 13 known negative control serum samples. The control
ELISA was repeated twice, resulting in 26 individual data points. Mean nor-
malised absorbance and Standard Deviation (SD) were both calculated from





A titration of different dilutions of plant-produced NP and mock antigen
were carried out using test positive and negative sera to determine which
dilutions to use for the test ELISA. Results of the titration of the recombi-
nant NP are shown in Table 4.2. The titration showed the expected results,
with the positive serum samples showing a decreasing signal as the antigen
dilution increased. The mock antigen shows a relatively stable signal across
all dilutions. A dilution of 1/400 (0,0025) of recombinant NP was selected for
further use in ELISAs as this concentration was the closest to the middle of
the measurable dynamic range, allowing for the most flexibility when reading
both strong and weak signals (Figure 4.1).
Table 4.2: Titration of recombinant NP and mock antigen to determine opti-
mum dilution for use in ELISAs. Absorbance was measured as the difference
between 405nm and 620nm. The reaction was visualised after 30 minutes.
Red colouring represents the maximum value, yellow the median and green
the minimum.
Dilution 1/50 1/100 1/200 1/400 1/800 1/1600 1/3200 1/6400
Positive5a 1,5030 1,0940 0,8330 0,4350 0,2630 0,2100 0,1860 0,1650
Positive5b 1,5240 1,0040 0,8730 0,4790 0,2790 0,2030 0,1590 0,1570
Negative5a 0,2460 0,2040 0,1630 0,1440 0,1290 0,1010 0,1190 0,1110
Negative5b 0,2170 0,1960 0,1680 0,1480 0,1390 0,1430 0,1410 0,1190
Positive5a 0,2120 0,2050 0,2140 0,1990 0,1950 0,1890 0,1850 0,1860
Positive5b 0,2110 0,1950 0,1610 0,1800 0,1640 0,1410 0,1650 0,1380
Negative5a 0,1350 0,1520 0,1240 0,1370 0,1230 0,1200 0,1220 0,1120



























Figure 4.1: Graph of serial dilutions of both NP and mock antigen to de-
termine the optimum dilution for further work ranging from 1/50 (0,02) to
1/6400 (0,00015625).
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4.3.2 Detection of anti-CCHFV antibodies in human
serum using plant produced NP.
To determine whether the plant-produced NP could accurately and reliably
detect the presence of antibodies against CCHFV in human serum, an indirect
ELISA was performed with 15 CCHFV positive (including 2, known highly
reactive positive samples) and 15 known negative serum samples.
The absorbance values of the negative samples were used to calculate
a cut-off value for determining a diagnostic positive reaction, as well as to
account for any possible background. The cut-off value is calculated as the
mean of the negative samples plus 2 standard deviations.
In Figure 4.2, negative serum samples are represented by numbers 1 to 15.
The positive serum samples are represented by numbers 16 to 30. The ELISA
was performed twice and each serum sample was measured in duplicate for
each repeat.
There is a significant difference between all positive and all negative sam-
ples, illustrated as the mean fraction of the highest value to the measured
sample, as well as the absence of any false positives.
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Negative sample value cut-off = 0.19
Mean of Negative Samples +2 Standard Deviations
Figure 4.2: Detection of anti-CCHFV IgG in an indirect ELISA, using plant
produced NP as a capture antigen. The error bars illustrate the variability




Traditional methods for diagnosis of CCHFV require high levels of bio-
containment for production of antigen, making the process both costly, as well
as potentially hazardous to the health of the individuals doing the testing
and the production of the antigen.
The recombinant CCHFV NP antigen tested in this work represents a
cheaper and safer alternative. It does not contain any live virus, eliminating
exposure risk in the production phase and reducing the risk in the testing
phase.
These results show that the antigen is capable of not only detecting
CCHFV IgG antibodies in the serum of individuals previously infected with
CCHFV, but it is also capable of distinguishing between the serum from a
previously infected individual and that of an individual with no known history
of CCHFV exposure.
The ability of the antigen to detect CCHFV IgG antibodies also shows us
that the plant produced antibody is likely being folded and processed correctly
by the plant hosts, leading to a protein conformation that is sufficiently
similar to the native protein to bind to native CCHFV NP antibodies. We
cannot however comment on the antigens antigenicity without further in-vivo
immunological studies.
Previously, CCHFV NP has been expressed in E. coli (Samudzi et al.,
2012), and showed similar results with regards to its ability to detect the
presence of CCHFV IgG antibodies in the serum of individuals who have
been previously infected by the virus as the plant produced NP used in this
study. However, the E. coli expression of CCHFV NP had issues with protein
solubility, leading to an increase in both cost and time required to purify the
protein. The NP expressed in N. benthamiana is soluble in standard protein
extraction buffers, simplifying the purification process.
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Further work is required to fully qualify the antigen for use in routine
diagnostics. This includes:
• Testing plant-produced NP against a larger range of negative samples
to validate the antigen and ensure that there is a comparatively low
level of false positives;
• Testing against a larger range of negative samples to ensure that there
is a comparatively low level of false positives;
• Comparison of sensitivity, specificity and reproducibility, against other
immunological diagnostic methods, such as virus neutralisation and
immunofluorescence; and
• Stability assays to determine the antigens long term stability under
different storage conditions. This is important as requirements such as
refrigeration or lyophilization add both cost and difficulty of access to
the diagnostic antigen.
A plant produced diagnostic antigen for CCHFV represents a cheap, safe
alternative to traditional antigen based diagnosis. Plant produced proteins
can be produced at large scale, but further work would be required to develop
a commercial scale expression and purification process.
Ready access to a CCHFV diagnostic assay could lead to increased epidemi-
ological surveillance, looking at viral prevalence in a range of hosts, including
humans, animals and insects.
Conclusion
In order to study the true risk that a virus holds, it is necessary to know
as much information as possible about its hosts, range, possible vectors, in-
fectivity and case fatality. Traditionally this information can be obtained by
performing large scale serological studies, looking for evidence of infection in
possible vectors, as well as a range of hosts, including ones that are potentially
asymptomatic, such as birds and livestock animals. Large studies of this kind
have been difficult due to the lack of a safe, affordable serological assay for
CCHFV.
To this end, the aim of this project was to express Crimean-Congo haeor-
rhagic fever virus nucleocapsid protein (NP) in N. benthamiana and to purify
it sufficiently for it to be used in an indirect ELISA to detect antibodies in
the serum of individuals previously exposed to CCHFV.
The gene encoding the NP was cloned into three different plant expression
vectors, pRIC-3.0-HT, pTRAc-HT and pEAQ-HT. The resulting vectors were
then used without and with co-expression of NSs, a TSWV protein that has
shown to improve expression by reducing post-translational gene silencing.
The replicating vector pRIC-3.0-HT used with NSs produced the highest
expression levels of NP when comparing the intensities of the 55kDa sized
NP band on a western blot. However, there was little or no change when
NSs was used with pTRAc-HT: it is possible that the plants respond to
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the high levels of foreign mRNA produced by the replicating pRIC-3.0-HT
amplicon, by triggering RNA silencing, a tool in the plant’s adaptive immune
system. pTRAc-HT does not replicate so does not produce as much mRNA
as pRIC-3.0-HT, so no silencing occurs, which negates the need for NSs.
To obtain sufficient NP for use in an ELISA, the expression of the protein
needed to be scaled up. This was done by infiltrating 20 plants, using vacuum
infiltration, resulting in 100-200 grams of leaf material after harvest.
In order to reduce the possibility of non-specific background in the ELISA
due to human antibodies reacting with plant proteins, as well as to concentrate
the protein, purification was required. A two-step approach was used: first,
a bulk salting out using ammonium sulphate, to both reduce the volume of
crude protein solution required for purification as well as to remove a large
amount of contaminating protein, specifically RuBisCO which accounts for
50 % of soluble leaf protein. The second step made use of the 6 x-histidine
tag fused to the N-terminus of the NP gene during cloning. The protein
was bound to and eluted from a nickel affinity column, resulting in a more
concentrated NP protein, as seen by the density of the 55kDa band on a
Coomassie stained SDS gel. Additionally, the protein was much more pure,
judged by the small number of extra bands present.
Purified plant-produced NP was successfully used as a capture antigen
in an ELISA to detect CCHFV-specific IgG in the serum of individuals
previously infected with the virus, as well as to distinguish between individuals
with no history of infection and those previously infected. The plant produced
protein compared favourably in its ability to detect CCHFV-specific IgG,
with E. coli produced NP, returning no false-positive results and correctly
identifying all of the CCHFV positive serum samples, as seen when using the
E. coli produced NP as described by (Samudzi et al., 2012). However further
work as described in Section 4.4, such as testing against larger positive and
negative serum panels and studies on inter-batch variability, is required to
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determine further how the plant produced protein compares to its E. coli
produced counterpart.
To improve the utility of plant produced NP as a diagnostic reagent,
further work could be done to determine the protein’s ability to bind CCHFV-
specific IgM antibodies, as these are sometimes present sooner during infection
than IgG antibodies and would be a useful indicator in diagnosing CCHFV
infection, sooner after exposure to the virus (?).
In order to qualify the protein for work in large scale serological studies,
it needs to be tested on a larger range of tissue, such as animal serum and
insect hemolymph (Vanhomwegen et al., 2012).
This study is the first report of a plant produced CCHFV NP. I hope
that this work is used to improve monitoring and surveillance of CCHFV in
animals populations as well as to improve the access to diagnostic services
by both reducing the cost and improving the safety of the assay. Finally, I
hope that others will build upon this work, by applying the lessons learnt in
CCHFV NP production, to other Bunyaviridae species such as Rift-Valley
Fever Virus and produce similar NP based, plant produced diagnostic antigens,
further improving the availability and safety of diagnosis.
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